Tuesday, August 18, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Aug 17, 2026
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
background ▾
- •Two gene therapy deaths in Chinese IITs linked to severe immune reactions from high-dose viral vector delivery went undisclosed for extended periods, exposing systemic regulatory and transparency failures in China's alternative pathway.
- •China's government issued Order 818 (effective May 2026) establishing tighter IIT requirements for trial design, preclinical safety, risk management, and subject screening, signaling regulatory course correction but with uncertain near-term impact on trial volume.
- •The deaths undermine recent U.S. expert advocacy (including from CAR-T pioneer Carl June) to emulate China's faster IIT model; the FDA now pursues its own 6-9 month phase 1 acceleration plan rather than adopting the Chinese two-tiered system.
HuidaGene Therapeuticsbase-editing therapy (experimental)CRISPR-based treatment for Duchenne muscular dystrophy
→ Read original articlePolicy•STAT News•Aug 18, 2026
Opinion: 8 steps to making surrogacy more ethical for everyone involved
background ▾
- •Surrogacy remains largely unregulated in the U.S., with no legal framework governing surrogate selection, intended parent eligibility, concurrent arrangements, or dispute resolution when complications arise
Policy•STAT News•Aug 18, 2026
Opinion: In parts of the world, antibiotic overuse isn’t the problem — underuse is
background ▾
- •High-income countries are overusing antibiotics—particularly broad-spectrum Watch drugs—while most LMICs are underusing them despite higher infectious disease burdens, inverting the standard narrative about AMR drivers
- •The study provides first-ever optimal antibiotic consumption benchmarks for 186 countries, enabling data-driven policy targets beyond simple reduction goals
- •Monitor implementation of the UN's 70% Access-category antibiotic target by 2030 and whether donor funding/supply chain initiatives shift to address underuse in resource-limited settings
Policy•Endpoints News•Aug 17, 2026
AI will be better than doctors at some medical tasks, healthcare and VC experts predict
background ▾
- •Industry consensus suggests AI will surpass physician performance in select clinical tasks within the next 5 years, though current tools operate under physician supervision
Policy•Fierce Biotech•Aug 17, 2026
Merck KGaA lays off 20 staffers in latest blow to US research team
background ▾
- •EMD Serono is reducing its Billerica workforce by 20 confirmed positions, with potential for 70 additional departures if employees don't comply with new onsite mandates
Merck KGaAEMD Serono
→ Read original articleMarket Access
Market Access•Fierce Biotech•Aug 17, 2026
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
background ▾
- •Slate secured $245M in new financing plus reverse merger with Fulcrum, providing runway into 2029 to advance SLTE-1009 (dual PACAP/VIP antagonist) and SLTE-2100 (bispecific CGRP/PACAP-VIP antibody) through mid-stage trials in migraine.
- •The dual PACAP/VIP mechanism is unvalidated in humans and faces direct competition from Lundbeck's more clinically advanced anti-PACAP program; Eli Lilly's prior failure of anti-PACAP in migraine adds execution risk.
- •Watch for phase 1 safety/PK readout (mid-2027) and phase 2 migraine efficacy data (H2 2026) to determine if dual blockade offers clinically meaningful benefit over single-mechanism PACAP or established CGRP antagonists that generated $5B in sales in 2025.
Slate MedicinesFulcrum TherapeuticsDartsBio PharmaceuticalsSLTE-1009SLTE-2100pociredir
→ Read original articleMarket Access•Endpoints News•Aug 17, 2026
Biotech's reverse merger renaissance poised to continue
background ▾
- •Reverse merger activity is resurging in biotech as an alternative to traditional IPOs for capital formation and market access
Market Access•Fierce Biotech•Aug 18, 2026
Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod
background ▾
- •Dersimelagon is pending FDA approval following positive Phase 3 data demonstrating near 30-minute delay in sun-induced symptom onset—a meaningful clinical endpoint for rare photodermatologic diseases with high unmet medical need
- •Leo gains competitive advantage over incumbent Scenesse via oral dosing versus every-8-weeks implant requirement, potentially capturing market share in a concentrated but underserved rare disease category
- •FDA decision timing and reimbursement landscape for rare dermatologic orphan drugs remain critical unknowns affecting deal value realization
Leo PharmaTanabe PharmaClinuvel PharmaceuticalsdersimelagonScenesseAdbry
→ Read original articleMarket Access•Fierce Biotech•Aug 17, 2026
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
background ▾
- •OmniAb's antibody platform and ion channel expertise continue attracting tier-1 pharma partnerships, validating its transgenic animal-derived antibody technology as a competitive advantage in a challenging drug class.
- •Lilly's $370M commitment signals continued industry interest in ion channel programs despite historical development difficulties, though lack of disclosed target limits assessment of true program value or probability of success.
Eli LillyOmniAbLigand PharmaceuticalsTecvayliramantamigBI 3802876
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Aug 17, 2026
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
background ▾
- •REGN7041 development halted mid-Phase 1/2a due to an unidentified safety event that worsened the risk-benefit calculus enough to warrant trial termination.
- •Anti-CD3 monotherapies in ophthalmic indications remain unproven clinically, whereas CD3-targeting bispecifics (like Lynozyfic and Kimmtrak) have achieved regulatory success in systemic and ocular oncology.
- •Watch for: Regeneron's next communication on REGN7041 status, any regulatory interactions regarding the safety finding, and whether the company pursues alternative CD3 approaches in eye disease.
RegeneronSanofiJohnson & JohnsonREGN7041LynozyficTzield
→ Read original articleClinical Trials•Fierce Biotech•Aug 17, 2026
Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate
background ▾
- •EVX-03 was discontinued after years of delay with no clinical trial ever initiated, despite 2022 claims of 'very encouraging' preclinical data, signaling potential challenges in translating in vitro findings to clinical development.
- •EVX-05 represents a strategic pivot to off-the-shelf cancer vaccines targeting ERV-antigens in glioblastoma, an unmet indication, with Duke partnership providing clinical development support through phase 1.
- •Monitor October readout of three-year EVX-01 melanoma data and initiation timeline for EVX-05 phase 1 trial; cash runway extension to H2 2027 provides runway but limits pivoting flexibility.
EvaxionDuke University School of MedicineEVX-03EVX-05EVX-04
→ Read original articleClinical Trials•Endpoints News•Aug 17, 2026
EyePoint’s bid to compete with Eylea falls flat
background ▾
- •EyePoint's Phase 3 candidate failed to meet superiority criteria versus Eylea in wAMD, a critical competitive failure in a blockbuster indication
- •Eylea maintains its entrenched position as the preferred treatment standard, limiting near-term competitive pressure despite ongoing biosimilar development
- •EyePoint must reassess its ocular pipeline strategy and may face investor pressure regarding development priorities and capital allocation
EyePoint PharmaceuticalsRegeneronEyleaEyePoint investigational eye treatment (unnamed in article)
→ Read original articleClinical Trials•Endpoints News•Aug 17, 2026
AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu
background ▾
- •AstraZeneca achieved positive Phase 3 readouts in two separate lung cancer trials, expanding pipeline optionality in a competitive oncology market
- •The Tagrisso-containing combination regimen represents a multi-drug strategy, while Enhertu data suggests single-agent efficacy in a potentially distinct patient population
- •Monitor for full data presentations at major oncology conferences and regulatory submissions; competitive positioning versus established lung cancer standards of care will be critical
AstraZenecaTagrissoEnhertuOrpathys
→ Read original articleClinical Trials•Endpoints News•Aug 17, 2026
Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China
background ▾
- •Ivonescimab received China approval for first-line lung cancer despite efficacy diminishing with longer follow-up—a concerning signal for the drug's clinical profile
- •Extended follow-up data showing reduced benefit suggests potential duration-of-response or progression concerns that differ from initial trial readouts
- •Key uncertainty: how extended follow-up efficacy compares to standard-of-care competitors and whether this affects commercial prospects beyond China
Summit TherapeuticsAkesoivonescimab
→ Read original article